Please use this identifier to cite or link to this item:
https://hdl.handle.net/20.500.12439/3534| Title: | A systematic review and Meta-Analysis ofMiddle meningeal artery embolization for Non-Acute Subdural Haematoma: A proposed treatment algorithm. | Northern Health Authors: | Hong Kuan Kok� | Northern Health affiliation: | (Kok) Interventional Radiology Service, Northern Imaging Victoria, Northern Health, Melbourne, Australia (Kok) NECTAR Research Group, Northern Health, Melbourne, Australia |
Authors: | Edward Liu J.; Barras C.D.; Shaygi B.; Kok H.K.; Pavlin-Premrl D.; Slater L.-A.; Gan C.; Gonzalvo A.; Smith P.D.; Russell J.; Jhamb A.; Moore J.; Maingard J.; Gauden A.; Khabaza A.; Chandra R.V.; Yazdabadi A.; Stevens S.; Brooks M.; Asadi H. | Citation: | Journal of Clinical Neuroscience. 147(no pagination), 2026. Article Number: 111917. Date of Publication: 01 May 2026. | Issue Date: | 1-May-2026 | Abstract: | Objective To synthesize the evidence from recent large randomized controlled trials (RCTs) on middle meningeal artery embolization (MMAE) for non-acute subdural haematoma (SDH) and to propose a unified, evidence-based treatment algorithm to guide clinical practice. Methods We conducted a systematic review and meta -analysis of large (n >= 100), multicentre RCTs comparing MMAE with surgical evacuation or conservative management for non-acute SDH. A comprehensive search of PubMed/MEDLINE, Embase, and CENTRAL was performed to August 2025. The primary outcome was treatment failure, a composite of radiological recurrence, symptomatic progression, or need for repeat surgery/surgical rescue at 90-180 days. Key secondary outcomes included functional status (modified Rankin Scale, mRS) and safety. Random-effects models were used for pooled analyses. Results Four RCTs involving 1,774 patients were included. For patients managed non-surgically, standalone MMAE was associated with a 64% relative risk reduction in treatment failure compared to conservative management (Risk Ratio [RR] 0.36, 95% CI [0.22, 0.60]). The number needed to treat was 4. As a surgical adjunct, MMAE offered a more modest but significant benefit in reducing recurrence or progression (RR 0.65, 95% CI [0.48, 0.89]). MMAE did not significantly improve functional outcomes or all-cause mortality but demonstrated a favourable safety profile with low rates of serious complications. Conclusions MMAE significantly reduces treatment failure in non-acute SDH, with the most profound benefit seen in non-surgical patients by lowering the need for surgical rescue. Its role as a routine surgical adjunct is less clear, suggesting a stratified approach for patients at high risk of recurrence.Copyright � 2026 The Author(s). | URI: | https://hdl.handle.net/20.500.12439/3534 | DOI: | https://dx.doi.org/10.1016/j.jocn.2026.111917 | PubMed URL: | https://pubmed.ncbi.nlm.nih.gov/41690054/ | Type: | Journal article | Study/Trial: | Systematic review and/or meta-analysis | Access Rights: | Open access | Place of publication: | United Kingdom | Journal Title: | Journal of Clinical Neuroscience |
| Appears in Collections: | Articles |
Show full item record
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.